Lynnet Koh, M.B.A.
Chairman & Founder

Ms. Koh is a serial entrepreuner/intrapreuner with extensive Senior and C-level executive experience in the biotech, wireless, internet, and consumer products industries. She has led top corporate priority major growth initiatives, created the vision, championed and led the successful development of major product/technology innovations and successful global market launch of best in class products that transformed various industries/markets and delivered over $2.5B in new revenues. Homes runs include the first Caller ID in the world (AT&T Bell Laboratories), the world’s first generation wireless systems that set the industry benchmarks for mobility, portability and quality (AT&T Bell Laboratories), first generation Voice over Internet System (Cisco Systems). Her core competencies and passion are that of leading mission impossible-type major technology innovation/new product development projects from idea to global commercialization, major revenue and market leadership achievement – and in the process, transforming the lives of people around the world and creating new markets and industries. In a general management capacity, she has built multiple teams and organizations from ground-up. Ms. Koh has also led numerous deals including, raising over $115MM for her various intrapreunerial/entrepreunerial startups, numerous M&A and licensing deals. MIT educated, she was in high potential executive leadership programs with industry leaders which provided her the hands on growth opportunity to demonstrate results in general management, brand management, sales leadership, new product development, product commercialization, P&L and market performance management.

Jim Caggiano

With nearly 30 years of experience in the biotech/pharmaceutical and medical device industries, Jim Caggiano is a seasoned and dynamic leader, Caggiano has a proven track record of creating value in turnaround situations and managing business transitions and exits.
He successfully directed the divestiture of Allergan’s LAP-BAND to Apollo Endosurgery in 2013, and later developed and implemented the strategy for Dendreon’s sale to Sanpower Group in 2017.
After the acquisition of Dendreon out of bankruptcy by Valeant for $415M in 2014, Caggiano was appointed to turn the enterprise to profitability and subsequently sold it to Sanpower holding for $820M in 2017, at which time he was appointed CEO of the Dendreon stand-alone company.
He is credited with Dendreon’s resurgence as an exciting and growing enterprise taking it from bankruptcy to producing in excess of $100m in annual EBIT in 4 years.
Earlier in his career, Caggiano held senior roles at Allergan, Inc., Abbott Laboratories, Valeant Pharmaceuticals, and TAP Pharmaceuticals.
Caggiano received a B.S. in agricultural economics (business) from Cornell University, which he attended on an Army scholarship and an M.B.A. from the Kellogg School of Management at Northwestern University.
Prior to entering the industry, Caggiano served as an officer in the Armor Branch of the United States Army further honing his leadership and execution skills.

Audrey Jakubowski, Ph.D.
Senior Vice President of Regulatory Affairs & Quality Assurance

Dr. Jakubowski came to Targazyme after a long career in both big and small pharma.  She started her career at Bristol Myers, working with dermatological products and then moving to the Bristol Myers Research Center in Wallingford, CT, where she built and led a regulatory group that focused on building a single, international dossier that could be submitted around the globe.  During that time, Dr. Jakubowski prepared registration plans and documents for drugs in the cancer, cardiovascular, central nervous system, anti-infective and anti-HIV areas for European, Canadian and Japanese submissions.   Dr. Jakubowski went on to DuPont, where she was the head of Global Regulatory Affairs for the pharmaceutical division at DuPont where she had responsibility for investigational drugs as well as marketed products, generic drugs and radiopharmaceuticals.   During her 15th years in big pharma, Dr. Jakubowski was responsible for submitting multiple New Drug Applications, both in the U. S. and abroad.  She also was the regulatory lead for two FDA advisory committee meetings in the U.S.  Dr. Jakubowski was an elected member of the Pharmaceutical Research and Manufacturer’s Association (PhRMA) Regulatory Affairs Committee and was an invited speaker at many professional meetings.  Dr. Jakubowski came to California to join Systemix, a cell therapy company, as their Vice President of Regulatory Affairs and Quality Assurance.  Dr. Jakubowski went on to SuperGen where she also had responsibility for regulatory affairs and quality assurance and submitted two NDAs for cancer drugs.  Dr. Jakubowski went on to support the company’s focus on new molecules that were early on in development, which she continued to do until she retired in 2009.  Dr. Jakubowski left retirement to join Targazyme because she feels that the platform technology that Targazyme has developed has the potential to help so many people who are desperate for help with their serious diseases.  Dr. Jakubowski received her Ph.D in Physical Chemistry from S.U.N.Y. Buffalo.  She also completed a PostDoctoral Fellowship at S.U.N.Y. Buffalo Department of Medicine and another at Rosewell Park Memorial Institute in Buffalo, N.Y.

Richard Martin, Ph.D. 
VP of CMC and Head of Operations

Dr. Martin is an accomplished pharmaceutical executive with over 20 years of research and development experience in the fields of antibacterial, inflammation, oncology, antiviral, antifungal, cardiovascular and metabolic diseases, sexual dysfunction, as well as glycosciences.  An excellent track record of bringing hits to leads, optimizing compounds into development candidates, as well as managing the chemistry, manufacturing, and regulatory activities for both clinical stage and approved drugs. He directed many successful programs of which 4 compounds have entered clinical trials. Collaborated closely with several Big Pharma companies to advance these development compounds following licensing of the assets and participated in joint steering teams.  He was instrumental in the CMC efforts that led to the approval of Apricus Biosciences’ first drug Vitaros® in Canada and Europe.  Dr. Martin initially served at Tanabe Research Laboratories before joining X-Ceptor therapeutics, which was acquired by Exelixis for their valuable metabolic disease programs.  He then held the position of Director of Chemistry at Exelixis before joining RetroVirox as Senior Director of Chemistry, founding partner and investor.  Dr. Martin then served as Vice President of Chemistry and Manufacturing at Apricus Biosciences (NexMed USA) where he led the chemistry, manufacturing and supply chain activities at the company.  Dr. Martin obtained his Ph.D. from the University of Toronto and pursued postdoctoral studies at The Scripps Research Institute in San Diego with professor Chi-Huey Wong, a pioneer in the field of glycosciences.  Dr. Martin has over 30 patent applications, 26 of which have already been granted in the US, over 25 publications in peer-reviewed journals and presentations at various scientific meetings.

David S. Smith, Ph.D.
Advisor for Regulatory Affairs and Quality Assurance

Dr. Smith is an astute strategic leader and creative problem-solver offering over 30 years of R&D and executive experience.  He is respected as a process authority with a well-earned reputation for planning, process improvement, and organizational flexibility.  Dr. Smith has been instrumental in achieving significant regulatory successes through team building and sound application of regulatory principles.  Dr. Smith also has a solid business background with extensive knowledge of strategic planning, risk management, product development, and lifecycle management. He is recognized for ability to use adaptive management techniques, processes and procedures to enhance business practices, increase productivity, and ensure compliance.

Dr. Smith started his career in clinical research and then moved to regulatory affairs at Schering-Plough. He enjoyed increasing responsibilities at Roche, Wyeth, Astex and Galena Biopharma, before coming to Targazyme.

Emmanuelle J Meuillet, PhD

VP of Research and Development

Emmanuelle J. Meuillet is an accomplished scientist, inventor and entrepreneur focusing on drug discovery and development. Dr. Meuillet obtained a PhD in Biochemistry and Pharmacology from the Louis Pasteur University (France). She completed post-doctoral training at the Children’s Memorial Hospital at Northwestern University in Chicago and at the University of Arizona Comprehensive Cancer Center in Tucson. Over the years, Dr. Meuillet has managed many NIH funded programs bringing in over $9M for research in oncology and experimental therapeutics. She is an experienced manager of national and international multidisciplinary innovative projects. She founded two biotech companies, Phusis Therapeutics, Inc. in 2009 and Theraxen Technologies, LLC in 2016 advancing the development of small molecules. Dr. Meuillet is a consultant for the NIH, DoD, and various foundations and organizations in the US and Europe. She is the author of more than fifty peer reviewed manuscripts and reviews, she is an inventor on three patents and she belong to several editorial boards for specialized cancer journals.